Moleculin Biotech Inc (NASDAQ:MBRX) saw a large growth in short interest in April. As of April 30th, there was short interest totalling 3,414,826 shares, a growth of 327.4% from the April 15th total of 798,955 shares. Based on an average daily volume of 19,748,725 shares, the short-interest ratio is currently 0.2 days. Currently, 12.4% of the shares of the company are sold short.
Shares of NASDAQ MBRX opened at $1.14 on Thursday. The company has a quick ratio of 2.06, a current ratio of 1.49 and a debt-to-equity ratio of 0.01. Moleculin Biotech has a 12 month low of $0.78 and a 12 month high of $3.15. The company has a market cap of $51.52 million, a price-to-earnings ratio of -2.24 and a beta of 2.26.
Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.05). As a group, equities research analysts forecast that Moleculin Biotech will post -0.37 earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new stake in Moleculin Biotech during the 4th quarter valued at approximately $36,000. Northern Trust Corp lifted its stake in Moleculin Biotech by 109.1% during the 4th quarter. Northern Trust Corp now owns 47,918 shares of the company’s stock valued at $50,000 after acquiring an additional 25,000 shares during the period. BB&T Corp lifted its stake in Moleculin Biotech by 55.6% during the 1st quarter. BB&T Corp now owns 140,000 shares of the company’s stock valued at $113,000 after acquiring an additional 50,000 shares during the period. Taylor Cottrill Erickson & Associates Inc. lifted its stake in Moleculin Biotech by 24.6% during the 1st quarter. Taylor Cottrill Erickson & Associates Inc. now owns 151,781 shares of the company’s stock valued at $123,000 after acquiring an additional 30,000 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in Moleculin Biotech by 279.0% during the 1st quarter. Renaissance Technologies LLC now owns 157,164 shares of the company’s stock valued at $127,000 after acquiring an additional 115,700 shares during the period. Institutional investors and hedge funds own 4.59% of the company’s stock.
WARNING: This article was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/moleculin-biotech-inc-mbrx-sees-large-increase-in-short-interest.html.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.